IRIS
TORRE, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.062
Totale 4.062
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.062
Totale 4.062
Salva come PNG Salva come JPEG
Città #
Genova 3.013
Rapallo 438
Genoa 336
Vado Ligure 270
Bordighera 5
Totale 4.062
Salva come PNG Salva come JPEG
Nome #
Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. 178
Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents 156
Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness? 150
A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? 149
Circadian secretion of melatonin and thyrotropin in hospitalized aged patients. 140
Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity. 132
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 123
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. 122
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. 117
Monotherapy with Pegylated Interferon Alpha-2a in Hemodialyzed Patients with Chronic Hepatitis C 111
Clearance kinetics of hepatitis C virus under different antiviral therapies. 111
Antiviral activity of amantadine in elderly patients with chronic hepatitis C 111
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden 109
Effects of pyridostigmine, corticotropin-releasing hormone and growth hormone-releasing hormone on the pituitary-adrenal axis and on growth hormone secretion in dementia. 109
Interferon retreatment in chronic hepatitis C: wich patients to choose, and what schedule to use 108
Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant 104
Evolution of wild-type and precore mutant HBV infection after liver transplantation. 104
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C 103
TT virus infection in haemodialysis patients 103
Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. 100
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. 100
Clinical implications of mutations in the hepatitis B virus genome. 96
Novel immunoassay for the detection of hepatitis B surface 'escape' mutants and its application in liver transplant recipients. 95
Elevations in ALT levels late the course of antiviral therapy in HCV-RNA negative patients are associated with virological relapse 94
Continuous lamivudine treatment in an OLT patient despite the appearance of HBV resistant strain: longitudinal analysis. 91
Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. 90
Hepatitis B virus variants with core gene deletions in the evolution of chronic hepatitis B infection. 90
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 90
Prospective evaluation of primary infection due to HCV, HGV or TTV in children with newly diagnosed neoplasia. 89
Amantadine: a different approach. 87
Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. 86
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 85
Chronic hepatitis C. New therapeutic strategies. 82
A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy 81
Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients 74
Sex hormones, gonadotropins and prolactin in male epileptic subjects in remission: role of the epileptic syndrome and of antiepileptic drugs. 73
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 73
Evaluation of a new hepatitis C virus sequecing assay as a routine method for genotyping 68
Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. 52
Erythrocytes cell wall defects correlate with the stage of liver cirrhosis 47
Totale 4.083
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.097
article - articoli 11.097
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.194
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020710 0 0 0 0 0 0 166 86 108 184 119 47
2020/2021275 11 31 18 31 29 22 11 29 23 31 21 18
2021/2022453 13 26 27 46 17 42 31 112 21 56 14 48
2022/2023536 59 58 7 45 81 90 3 48 86 5 48 6
2023/2024224 7 37 3 31 22 34 5 8 13 1 28 35
2024/2025291 30 43 11 54 96 57 0 0 0 0 0 0
Totale 4.083